Aileron Therapeutics (NASDAQ:ALRN) major shareholder Apple Tree Partners Ii Lp sold 107,904 shares of the firm’s stock in a transaction that occurred on Thursday, April 19th. The shares were sold at an average price of $6.31, for a total transaction of $680,874.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of NASDAQ ALRN traded down $0.79 during midday trading on Thursday, reaching $6.01. 263,411 shares of the stock were exchanged, compared to its average volume of 31,640. The stock has a market cap of $102.99 and a price-to-earnings ratio of -3.40. Aileron Therapeutics has a 12 month low of $5.82 and a 12 month high of $15.48.
Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings results on Monday, April 2nd. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). analysts forecast that Aileron Therapeutics will post -2.06 EPS for the current fiscal year.
Separately, Zacks Investment Research raised shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Aileron Therapeutics currently has an average rating of “Buy” and an average price target of $19.33.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System bought a new position in shares of Aileron Therapeutics during the third quarter worth $110,000. Vanguard Group Inc. bought a new position in shares of Aileron Therapeutics during the second quarter worth $111,000. Bank of New York Mellon Corp bought a new position in shares of Aileron Therapeutics during the third quarter worth $135,000. Schwab Charles Investment Management Inc. bought a new position in shares of Aileron Therapeutics during the third quarter worth $165,000. Finally, Endurant Capital Management LP boosted its position in shares of Aileron Therapeutics by 24.0% during the fourth quarter. Endurant Capital Management LP now owns 85,997 shares of the company’s stock worth $906,000 after purchasing an additional 16,647 shares in the last quarter. 7.62% of the stock is currently owned by institutional investors.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.